Financials
Financial year 2025
MEDGENIX BENELUX from Wevelgem, company number BE0407171356, closed financial year 2025 with a result of € 1.9 million after tax. For that financial year MEDGENIX BENELUX recorded revenue of € 42.9 million and equity of € 17.5 million. Compared with financial year 2023, the result moved from € 2.6 million to € 1.9 million. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
€ 17.5 million
▼ 37% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.9 million
▼ 26% vs 2023
Profit after tax over the fiscal year.
€ 14.7 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
122.3
▲ 1.8 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 9.2 million
▲ 6% vs 2023
€ 75,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 23,732
▼ 57% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 5.7 million
▲ 40% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 76 days on average.
€ 1.5 million
▼ 6% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2025 | Change 2023 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 31,495,241 | € 35,920,245 | € 40,368,924 | € 42,899,280 | ▲ 6% |
| Profit after taxes | € 1,458,168 | € 833,944 | € 2,581,084 | € 1,898,905 | ▼ 26% |
| Equity | € 24,623,404 | € 25,457,348 | € 28,038,431 | € 17,542,010 | ▼ 37% |
| Total debts | € 6,220,873 | € 8,503,945 | € 8,025,472 | € 21,888,278 | ▲ 173% |
| Cash | - | - | € 14,614 | - | |
| Land & buildings | € 3,896,975 | € 4,639,698 | € 4,370,600 | € 5,698,290 | ▲ 30% |
| Retained profit | € 13,944,301 | € 14,778,245 | € 17,359,329 | € 6,862,907 | ▼ 60% |
| Dividend | € 0 | € 0 | € 0 | € 14,700,000 | |
| Balance sheet total | € 30,892,455 | € 33,984,337 | € 36,080,675 | € 39,430,288 | ▲ 9% |
| Employees (FTE) | 133.9 | 126.5 | 120.5 | 122.3 | ▲ 1.8 |
Key figures of MEDGENIX BENELUX, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDGENIX BENELUX?
What happened at MEDGENIX BENELUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Geert Florizoone stepped down as director. NBB
- Magali Verbraeken stepped down as director. NBB
- Anja Van Winsberghe stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 1.9 million (▼ 26% vs 2023). Source: NBB ↗
- Geert Florizoone became a director. NBB
- Magali Verbraeken became a director. NBB
- Anja Van Winsberghe became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 1.5 million profit in 2021 to € 1.9 million profit in 2025.
Paid € 2.7 million in corporate taxes since 2021.
Best year ever: 2023, with € 2.6 million profit.
Paid out € 14.7 million in dividends to the owners in total.
A new publication or filing at MEDGENIX BENELUX? We notify you, reason included.
Follow MEDGENIX BENELUXDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Perrigo Belgium NV (100%).
Directors
According to the 2025 annual accounts
Magali Verbraeken
Director
Also active at: OMEGA PHARMA TRADING, Perrigo Belgium, Perrigo Capital, Perrigo Europe Invest, Oce-Bio, JAICO R.D.P., OMEGA PHARMA INTERNATIONAL, OMEGA PHARMA INNOVATION & DEVELOPMENT
since 2024 · until 2030
Anja Van Winsberghe
Director
Also active at: OMEGA PHARMA TRADING, Perrigo Belgium, Perrigo Capital, Perrigo Holding, Perrigo Europe Invest, Oce-Bio, JAICO R.D.P., HRA PHARMA BENELUX +2 more
since 2020 · until 2026
Geert Florizoone
Director
since 2024 · until 2030
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Vliegveld 21
8560 Wevelgem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
NEDZONE-AS, NL
Website info
Features
Security
Details
- Company number
- 0407.171.356
- VAT number
- BE 0407.171.356
- Registered office
- Vliegveld 21, 8560 Wevelgem
- Names & denominations
- MEDGENIX BENELUX
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 21 June 1970
- Peppol
- Active · Active since 8 Dec 2025
- Contact
- medgenix.be
- Activities · NACE
Vervaardiging van geneesmiddelen
Vervaardiging van overige chemische producten
Vervaardiging van andere chemische producten, neg